ArticleJournal of clinical and translational science2026
Impact evaluation of the Hypertension Treatment in Nigeria program using the Translational Science Benefits Model.
Article in Journal of clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04158154 (Transforming Hypertension Treatment in Nigeria Using a Type II Hybrid, Interrupted Time Series Design), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Transforming Hypertension Treatment in Nigeria Using a Type II Hybrid, Interrupted Time Series Design
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypertension is a leading cause of cardiovascular disease with significant burden experienced in low-and middle-income countries. The Hypertension Treatment in Nigeria (HTN) Program implemented a large-scale hypertension treatment program in the Federal Capital Territory (FCT) of Nigeria. Identification of benefits is important to acknowledge and demonstrate the value of research beyond evaluation of pre-identified scientific outcomes. This manuscript aims to identify the benefits and impact of the HTN Program using the Translational Science Benefits Model (TSBM). Methods: The HTN Program was a type II interrupted time series trial conducted from January 2020 to December 2023 to evaluate effectiveness and implementation of a multilevel hypertension control program in 60 primary healthcare centers in Nigeria. TSBM benefits were identified and verified by cataloging events, results, and procedures and aligning using the Translating for Impact Toolkit. The domains include policy, community, clinical, economic, and a new fifth domain, capacity building. Results: The HTN Program enrolled 21,922 patients. Hypertension treatment increased from 86.8% (95%CI: 86.5%, 87.2%) at baseline to 96.2% (95%CI: 96.0%, 96.4%) at the end of the study period. Hypertension control also increased from 22.3% (95%CI: 21.7%, 22.9%) at baseline to 56.4% (95%CI: 55.9%, 56.8%). Thirty-three TSBM benefits were identified across five domains. Most benefits were identified in the policy (9), capacity building (9), and community (7) domains. Conclusion: The HTN Program not only improved hypertension treatment and control in primary care in the FCT of Nigeria but also demonstrated broader impacts beyond its initial effectiveness and implementation objectives supporting program sustainment and scale-up.Trial Registration: NCT04158154.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.